Insights into the biology of diabetic vascular disease: what's new?
James R Sowers1, Craig S Stump
1Center for Diabetes and Cardiovascular Health, University of Missouri, Columbia, Missouri 65212, USA. Sowersj@health.missouri.edu
Insights
Diabetic cardiovascular disease (CVD) risk is high due to hyperglycemia and hypertension. Controlling blood pressure with multiple agents, including renin-angiotensin-aldosterone system blockers, is crucial for preventing cardiovascular events in diabetes.
Area of Science:
- Endocrinology
- Cardiology
- Nephrology
Background:
- Cardiovascular disease (CVD) is a leading cause of death in diabetic individuals, with a 3-4 fold increased risk.
- Diabetes is characterized by hyperglycemia, hypertension, dyslipidemia, inflammation, and impaired thrombolysis, all contributing to CVD.
- The renin-angiotensin-aldosterone system (RAAS) plays a key role in mediating cardiovascular dysfunction in diabetes, linked to insulin resistance and obesity.
Purpose of the Study:
- To review the pathophysiologic mechanisms linking diabetes and cardiovascular disease.
- To discuss evidence-based strategies for CVD prevention in diabetic patients.
- To highlight the importance of blood pressure control and RAAS blockade.
Main Methods:
- Review of existing clinical trials and pathophysiologic investigations.
- Analysis of data on CVD risk factors in diabetes.
- Evaluation of therapeutic interventions for CVD prevention.
Main Results:
- Hypertension is a primary driver of CVD in diabetes.
- Multiple antihypertensive agents are often required to achieve blood pressure goals (<130/80 mm Hg).
- RAAS blocking agents reduce blood pressure and offer cardiovascular and renal protection, with benefits extending beyond BP reduction.
Conclusions:
- Aggressive blood pressure management is essential for reducing cardiovascular risk in diabetes.
- RAAS blockade is a key therapeutic strategy for managing hypertension and protecting against CVD and renal disease in diabetic patients.
- Comprehensive strategies addressing hyperglycemia, dyslipidemia, and inflammation are necessary for holistic CVD prevention.
Abstract:
The major cause of morbidity and mortality in persons with diabetes is cardiovascular disease (CVD), the risk of which is increased three- to four-fold versus persons without diabetes. The biology of diabetes is characterized not only by hyperglycemia but also by hypertension, dyslipidemia, microalbuminuria, inflammation, and abnormal thrombolysis. Hypertension is a common feature of diabetes and is the primary contributor to CVD. Recent investigations have revealed a relationship between vascular derangements, insulin resistance, and visceral obesity and have implicated the renin-angiotensin-aldosterone system (RAAS) as a key mediator of cardiovascular dysfunction in diabetes. Angiotensin II has been shown to have direct effects on endothelial dysfunction, oxidative stress, inflammation, skeletal muscle, and adipocyte function. These pathophysiologic considerations have formed the basis for CVD prevention strategies in diabetes. Clinical trials have demonstrated a reduction in cardiovascular events with aspirin, lipid-lowering agents, and antihypertensive agents. Blood pressure (BP) control (<130/80 mm Hg) is a crucial component of risk reduction, and several studies have demonstrated the need for multiple agents to reach therapeutic goals. Clinical trials also demonstrated the benefit of RAAS blocking agents in reducing BP and cardiovascular and renal risk, and suggest clinical benefits beyond BP reduction.
Related Concept Videos
01:27Diabetic Retinopathy
01:22Diabetic Neuropathy
01:31Diabetic Foot Ulcer
01:28Diabetic Nephropathy
01:24Type II Diabetes II: Pathophysiology
01:20Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...